Zentalis Pharmaceuticals IncNASDAQ:ZNTL
- LAST PRICE8.3900
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.3600/ 2
- Ask / Lots13.3400/ 1
- Open / Previous Close0.0000 / 8.3900
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ZNTL |
|---|---|---|
| 09:32 ET | 5599 | 8.835 |
| 09:34 ET | 600 | 8.765 |
| 09:36 ET | 500 | 8.78 |
| 09:38 ET | 750 | 8.83 |
| 09:39 ET | 13904 | 8.73 |
| 09:41 ET | 600 | 8.775 |
| 09:43 ET | 2905 | 8.68 |
| 09:45 ET | 1000 | 8.6501 |
| 09:48 ET | 1105 | 8.79 |
| 09:50 ET | 900 | 8.73 |
| 09:52 ET | 900 | 8.84 |
| 09:54 ET | 2698 | 8.711 |
| 09:56 ET | 5184 | 8.75 |
| 09:57 ET | 4924 | 8.8 |
| 09:59 ET | 800 | 8.82 |
| 10:01 ET | 2100 | 8.735 |
| 10:03 ET | 1361 | 8.7 |
| 10:06 ET | 15934 | 8.555 |
| 10:08 ET | 2158 | 8.51 |
| 10:10 ET | 816 | 8.49 |
| 10:12 ET | 1050 | 8.495 |
| 10:14 ET | 1599 | 8.45 |
| 10:15 ET | 2639 | 8.49 |
| 10:17 ET | 3000 | 8.49 |
| 10:19 ET | 2931 | 8.39 |
| 10:21 ET | 6590 | 8.345 |
| 10:24 ET | 1451 | 8.33 |
| 10:26 ET | 1150 | 8.34 |
| 10:28 ET | 2223 | 8.375 |
| 10:30 ET | 73044 | 8.325 |
| 10:32 ET | 10008 | 8.465 |
| 10:33 ET | 11475 | 8.495 |
| 10:35 ET | 3887 | 8.58 |
| 10:37 ET | 875 | 8.54 |
| 10:39 ET | 2128 | 8.585 |
| 10:42 ET | 200 | 8.56 |
| 10:44 ET | 350 | 8.52 |
| 10:46 ET | 1000 | 8.59 |
| 10:48 ET | 300 | 8.6 |
| 10:50 ET | 900 | 8.6 |
| 10:51 ET | 1400 | 8.605 |
| 10:53 ET | 1400 | 8.625 |
| 10:55 ET | 2223 | 8.54 |
| 10:57 ET | 600 | 8.52 |
| 11:00 ET | 842 | 8.49 |
| 11:02 ET | 2134 | 8.52 |
| 11:04 ET | 720 | 8.525 |
| 11:06 ET | 1704 | 8.5 |
| 11:08 ET | 975 | 8.45 |
| 11:09 ET | 618 | 8.46 |
| 11:11 ET | 7636 | 8.5 |
| 11:13 ET | 2860 | 8.49 |
| 11:15 ET | 396 | 8.46 |
| 11:18 ET | 400 | 8.45 |
| 11:20 ET | 400 | 8.4 |
| 11:22 ET | 700 | 8.41 |
| 11:24 ET | 600 | 8.41 |
| 11:26 ET | 1700 | 8.44 |
| 11:27 ET | 5168 | 8.415 |
| 11:29 ET | 800 | 8.41 |
| 11:31 ET | 1629 | 8.42 |
| 11:33 ET | 621 | 8.4 |
| 11:36 ET | 6525 | 8.36 |
| 11:38 ET | 800 | 8.36 |
| 11:40 ET | 2780 | 8.36 |
| 11:42 ET | 2250 | 8.4 |
| 11:44 ET | 6054 | 8.4 |
| 11:45 ET | 4700 | 8.43 |
| 11:47 ET | 1425 | 8.43 |
| 11:49 ET | 1875 | 8.4 |
| 11:51 ET | 950 | 8.4 |
| 11:54 ET | 1030 | 8.41 |
| 11:56 ET | 1100 | 8.415 |
| 11:58 ET | 2329 | 8.405 |
| 12:00 ET | 1379 | 8.4 |
| 12:02 ET | 4594 | 8.41 |
| 12:03 ET | 7895 | 8.385 |
| 12:05 ET | 2080 | 8.4 |
| 12:07 ET | 1024 | 8.41 |
| 12:09 ET | 3978 | 8.4 |
| 12:12 ET | 646 | 8.4 |
| 12:14 ET | 3352 | 8.41 |
| 12:16 ET | 2506 | 8.485 |
| 12:18 ET | 1263 | 8.49 |
| 12:20 ET | 1067 | 8.5076 |
| 12:21 ET | 672 | 8.49 |
| 12:23 ET | 4806 | 8.45 |
| 12:25 ET | 3773 | 8.46 |
| 12:27 ET | 4970 | 8.5 |
| 12:30 ET | 623 | 8.5 |
| 12:32 ET | 710 | 8.505 |
| 12:34 ET | 300 | 8.5185 |
| 12:36 ET | 1100 | 8.5185 |
| 12:38 ET | 963 | 8.49 |
| 12:39 ET | 1255 | 8.49 |
| 12:41 ET | 400 | 8.5 |
| 12:43 ET | 5040 | 8.52 |
| 12:45 ET | 1413 | 8.47 |
| 12:48 ET | 433 | 8.4885 |
| 12:50 ET | 336 | 8.475 |
| 12:52 ET | 909 | 8.5085 |
| 12:54 ET | 801 | 8.525 |
| 12:56 ET | 300 | 8.51 |
| 12:57 ET | 900 | 8.53 |
| 12:59 ET | 603 | 8.525 |
| 01:03 ET | 300 | 8.54 |
| 01:06 ET | 200 | 8.55 |
| 01:08 ET | 649 | 8.56 |
| 01:10 ET | 4543 | 8.53 |
| 01:12 ET | 4098 | 8.53 |
| 01:15 ET | 4938 | 8.555 |
| 01:17 ET | 6608 | 8.54 |
| 01:19 ET | 933 | 8.53 |
| 01:21 ET | 500 | 8.54 |
| 01:24 ET | 778 | 8.48 |
| 01:26 ET | 500 | 8.49 |
| 01:28 ET | 1400 | 8.5 |
| 01:30 ET | 30600 | 8.495 |
| 01:32 ET | 3312 | 8.511 |
| 01:33 ET | 2356 | 8.52 |
| 01:35 ET | 2200 | 8.545 |
| 01:37 ET | 500 | 8.52 |
| 01:39 ET | 2172 | 8.535 |
| 01:42 ET | 320 | 8.54 |
| 01:44 ET | 2400 | 8.57 |
| 01:46 ET | 1956 | 8.54 |
| 01:50 ET | 200 | 8.54 |
| 01:51 ET | 3620 | 8.52 |
| 01:53 ET | 4048 | 8.54 |
| 01:55 ET | 100 | 8.54 |
| 02:00 ET | 400 | 8.53 |
| 02:02 ET | 1900 | 8.51 |
| 02:04 ET | 11176 | 8.45 |
| 02:06 ET | 885 | 8.455 |
| 02:08 ET | 4304 | 8.5 |
| 02:09 ET | 1425 | 8.5299 |
| 02:11 ET | 1100 | 8.5 |
| 02:13 ET | 826 | 8.52 |
| 02:15 ET | 905 | 8.505 |
| 02:18 ET | 3452 | 8.47 |
| 02:20 ET | 977 | 8.455 |
| 02:22 ET | 1867 | 8.42 |
| 02:24 ET | 1111 | 8.42 |
| 02:26 ET | 2474 | 8.43 |
| 02:27 ET | 253 | 8.45 |
| 02:29 ET | 800 | 8.44 |
| 02:31 ET | 1848 | 8.43 |
| 02:33 ET | 1270 | 8.42 |
| 02:36 ET | 5177 | 8.39 |
| 02:38 ET | 1444 | 8.4 |
| 02:40 ET | 1826 | 8.43 |
| 02:42 ET | 1240 | 8.45 |
| 02:44 ET | 2202 | 8.42 |
| 02:45 ET | 400 | 8.42 |
| 02:47 ET | 2254 | 8.42 |
| 02:49 ET | 600 | 8.44 |
| 02:51 ET | 655 | 8.45 |
| 02:54 ET | 3946 | 8.41 |
| 02:56 ET | 1509 | 8.405 |
| 02:58 ET | 2097 | 8.39 |
| 03:00 ET | 663 | 8.37 |
| 03:02 ET | 400 | 8.36 |
| 03:03 ET | 556 | 8.38 |
| 03:05 ET | 1560 | 8.38 |
| 03:07 ET | 1405 | 8.37 |
| 03:09 ET | 1610 | 8.355 |
| 03:12 ET | 4594 | 8.4 |
| 03:14 ET | 1914 | 8.41 |
| 03:16 ET | 9114 | 8.41 |
| 03:18 ET | 6105 | 8.385 |
| 03:20 ET | 6491 | 8.38 |
| 03:21 ET | 4836 | 8.4 |
| 03:23 ET | 3707 | 8.39 |
| 03:25 ET | 100 | 8.4 |
| 03:27 ET | 1051 | 8.4 |
| 03:30 ET | 3152 | 8.38 |
| 03:32 ET | 4657 | 8.39 |
| 03:34 ET | 2011 | 8.39 |
| 03:36 ET | 650 | 8.385 |
| 03:38 ET | 1365 | 8.38 |
| 03:39 ET | 1926 | 8.38 |
| 03:41 ET | 14644 | 8.395 |
| 03:43 ET | 611 | 8.395 |
| 03:45 ET | 8202 | 8.355 |
| 03:48 ET | 795 | 8.35 |
| 03:50 ET | 5827 | 8.355 |
| 03:52 ET | 2863 | 8.345 |
| 03:54 ET | 9207 | 8.34 |
| 03:56 ET | 15152 | 8.32 |
| 03:57 ET | 25691 | 8.35 |
| 03:59 ET | 157582 | 8.39 |
Jun 3, 2024
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 6:00PM ET on Monday Jun 03, 2024 by Dow Jones
6:00PM ET on Monday Jun 03, 2024 by Dow Jones
May 30, 2024
Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference, from 7:00AM ET on Thursday May 30, 2024 by Dow Jones
7:00AM ET on Thursday May 30, 2024 by Dow Jones
May 29, 2024
Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors, from 7:00AM ET on Wednesday May 29, 2024 by Dow Jones
7:00AM ET on Wednesday May 29, 2024 by Dow JonesPress Release: Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors, from 7:00AM ET on Wednesday May 29, 2024 by Dow Jones
7:00AM ET on Wednesday May 29, 2024 by Dow Jones
May 23, 2024
Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting, from 5:01PM ET on Thursday May 23, 2024 by Dow Jones
5:01PM ET on Thursday May 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Zentalis Pharmaceuticals Inc | 627.8M | -2.5x | --- |
Arrivent Biopharma Inc | 626.3M | 0.0x | --- |
Mineralys Therapeutics Inc | 624.6M | -5.6x | --- |
GH Research PLC | 623.8M | -18.1x | --- |
ProKidney Corp | 632.5M | -5.1x | --- |
Oculis Holding AG | 550.3M | -6.4x | --- |
Company Information
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
Contact Information
- Headquarters
- 1359 Broadway, Suite 801NEW YORK, NY, United States 10018
- Phone
- 212-433-3791
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- David Johnson
- President, Executive Director
- Cam Gallagher
- President, Chief Executive Officer, Director
- Kimberly Blackwell
- Chief Financial Officer, Treasurer
- Melissa Epperly
- Chief Operating Officer
- Iris Roth
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $627.8M |
|---|---|
Revenue (TTM) | $40.6M |
Shares Outstanding | 71.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.79 |
EPS | $-3.36 |
Book Value | $6.18 |
P/E Ratio | -2.5x |
Price/Sales (TTM) | 15.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -639.35% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
